CORT continues Dallas-Fort Worth leadership in clinical trials for patients with advanced and metastatic melanoma with its ongoing study BMS CA-185006 of the BMS-663513 drug, an agonist of the CD137 immune cell regulatory protein. CD137 stimulates cell-mediated anti-melanoma tumor immunity. Studies have demonstrated that stimulation of CD137 may enhance anti-tumor immune responses against melanoma. BMS-663513 is a stimulator of CD137.
Patients who have failed first-line therapy for advanced unresectable or metastatic melanoma are eligible, if they meet other criteria. Patients who have not yet had first-line therapy for their disease are eligible for other melanoma studies at CORT. For more information about this important study, call 972-566-5588 (Dallas) or 972-981-4012 (Plano), and ask to speak with a Research Coordinator. Further information about CORT and CORT studies is available at www.CORTPA.com.
Tags: BMS 663513, CD137, Melanoma, metastatic melanoma, Stage IV Melanoma
June 6, 2008 at 9:30 pm |
[...] bmirtsching wrote an interesting post today onHere’s a quick excerptCORT continues Dallas-Fort Worth leadership in clinical trials for patients with advanced and metastatic melanoma with its ongoing study BMS CA-185006 of the BMS-663513 drug, an agonist of the CD137 immune cell regulatory protein. … [...]